BioSpace News Archive

Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI).

iTeos Therapeutics, Inc. (Nasdaq: ITOS), today announced the presentation of new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), today announced a conference call to provide updates and discuss strategy, as well as the resignation of Thomas Farb and Agnieszka Winkler as members of the Company’s Board of Directors (the “Board”), effective December 5, 2021.

IN8bio, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its proprietary DeltEx platform, announced the promotion of Kate Rochlin, Ph.D. to Chief Operating Officer.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2021.

Johnson & Johnson announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization for the World Health Organization supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above.

Chesapeake Urology physician Andrew Harbin, MD, was the first urologist in Maryland to perform the new, minimally invasive robotic surgical procedure called Aquablation for the effective treatment of BPH/enlarged prostate symptoms.

Helix BioPharma Corp., a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, announced financial results for the 2021 fiscal year ended July 31, 2021.

Simcere Pharmaceutical Group and Aeromics, Inc. today announced that Simcere dosed the first subjects in the SIM0307 (AER-271) Phase I study conducted in Beijing Tiantan Hospital.

CANbridge Pharmaceuticals, Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development, and commercialization of transformative therapies, was officially listed on the Main Board of the Stock Exchange of Hong Kong Limited.